1. Introduction {#sec1-jcm-08-00506}
===============

Transcatheter aortic valve replacement (TAVR) has become the standard of care in patients with severe symptomatic aortic valve stenosis and who are at intermediate or high surgical risk \[[@B1-jcm-08-00506],[@B2-jcm-08-00506]\]. Despite recent advances, a wide range of ischemic and bleeding complications might mitigate the beneficial effect of TAVR procedures \[[@B3-jcm-08-00506]\]. Although early stent valve thrombosis after TAVR remains a rare complication, recent reports have emphasized that subclinical leaflet thrombosis (SLT) is detected in a sizeable proportion of patients (7--15%) with normal echocardiographic parameters. Early strokes (\<48 h) are mainly linked to periprocedural debris embolization and are unlikely to be targeted by antithrombotic regimen. The one-year stroke rate and thromboembolic complications incidence after TAVR vary from 2 to 3% \[[@B4-jcm-08-00506]\]. Multidetector computed tomography (MDCT) has emerged as the gold standard in the TAVR prosthesis sizing assessment and more recently contrast-enhanced MDCT has emerged to detect post-TAVR asymptomatic leaflet thrombosis \[[@B5-jcm-08-00506]\]. Hypoattenuation affecting motion (HAM) corresponds to SLT and is characterized by hypoattenuation leaflet thickening (HALT) and concomitant reduction in leaflet motion (RELM) evidenced by MDCT or by the elevation of the mean aortic transvalvular gradient ≥20 mmHg or increase more than 10 mmHg compared with baseline \[[@B6-jcm-08-00506]\]. Up to now, the clinical repercussion of these imaging findings remains unclear. Recently, special attention was given to their eventual role in the increase of thromboembolic events but also on bioprosthetic valve dysfunction and durability. Given the frequency of incidental SLT, the adequacy of current antithrombotic/antiplatelet strategies has been questioned and various ongoing trials (ATLANTIS, POPular-TAVI, ENVISAGE-TAVI, AUREA, and AVATAR trials) will undoubtedly refine optimal strategies. Tailoring the antithrombotic therapy after TAVR is particularly challenging because the high-risk profile of this commonly elderly population leads to a significant overlap in the risk of both ischemic and bleeding events. To avoid ischemic complications, full-dose anticoagulation (usually intravenous heparin) is administered during the TAVR procedure and dual antiplatelet therapy (DAPT) by aspirin plus clopidogrel has been the recommended antithrombotic treatment, following the procedure \[[@B1-jcm-08-00506],[@B2-jcm-08-00506]\] based on the empiric extrapolation of the percutaneous coronary intervention (PCI) experience. Current guidelines recommend the use of DAPT with aspirin and clopidogrel after TAVR to obviate the metallic stent mediated risk of thrombosis/embolization followed by long-term single antiplatelet therapy with aspirin alone. Oral anticoagulant's (OAC) use has being restricted to patients with another indication of OAC---mainly atrial fibrillation. In the last two decades, several studies have emphasized that high platelet reactivity under P2Y~12~-inhibitors has been associated with increased risk of ischemic events including stent thrombosis and also cerebrovascular events \[[@B7-jcm-08-00506]\]. By contrast, patients with extremely low platelet reactivity were demonstrated to be at increased risk of bleeding without any further benefit in stent thrombosis \[[@B8-jcm-08-00506]\].

In the present study, we sought to investigate (i) the prevalence of HAM and HALT after TAVR detected by MDCT, (ii) predictors of SLT, and (iii) the impact of OAC and platelet inhibition extent assessed by platelet reactivity index vasodilator stimulated phosphoprotein (PRI-VASP) and closure time adenosine diphosphate (CT-ADP) on SLT.

2. Materials and Methods {#sec2-jcm-08-00506}
========================

2.1. Study Design and Patients {#sec2dot1-jcm-08-00506}
------------------------------

From 1 August 2017 to 31 March 2018, 187 consecutive patients underwent TAVR at our institution (Nouvel Hôpital Civil, Université de Strasbourg, France). The indication for TAVR and vascular access sites were assessed by the local heart team. The protocol was approved by the local ethics committee. All participants gave their informed written consent before the procedure and agreed to the anonymous processing of their data (France 2 Registry). Patients received aspirin (75 mg to 160 mg) and clopidogrel (300 mg for loading dose and 75 mg/day for maintenance dose) before TAVR, with ongoing DAPT after the procedure for 3 months. The loading of clopidogrel was not performed when the patient was under chronic clopidogrel therapy. In patients treated with OAC, clopidogrel was not administered, and OAC plus aspirin were continued for 3 months. Routinely, OAC therapy was discontinued 5 days prior to the procedure. CT imaging was planned at discharge. Of these patients, 90 had high-resolution cardiac CT performed at various times after TAVR. In the presence of HAM, OAC therapy was initiated and a new contrast MDCT was performed in the follow up to assess consistent regression of HAM images. Ninety-seven patients did not perform post-TAVR contrast MDCT due to death, severe impaired renal function (glomerular filtration rate ≤30 mL/min/1.73 m^2^) or loss of follow-up ([Figure 1](#jcm-08-00506-f001){ref-type="fig"}).

2.2. Study Devices and Procedures {#sec2dot2-jcm-08-00506}
---------------------------------

For TAVR, the balloon-expandable Edwards SAPIEN XT or S3 prosthesis (Edwards Lifesciences, Irvine, CA, USA) and the self-expandable CoreValve or Evolut-R (Medtronic, Irvine, CA, USA) were used. During the procedure, 100 IU/kg of unfractionated heparin was administered to achieve an activated clotting time of 250 to 350 s. At the end of the procedure, heparin was antagonized with 100 IU/kg of protamine.

2.3. Blood Samples {#sec2dot3-jcm-08-00506}
------------------

Whole blood samples were collected the day before and 24 h after TAVR. Blood samples were immediately collected into a sodium citrate tube (VD Vacutainer® sodium citrate tubes) and sent to the haemostasis laboratory (EFS Alsace, France) for a platelet VASP phosphorylation analysis within 48 h. A standardized flow cytometric assay (Platelet VASP, Biocytex, Diagnostica Stago, Asnières, France) was used to assess VASP phosphorylation in all patients. VASP phosphorylation levels reflect P2Y~12~ inhibition and are expressed as the platelet reactivity index (PRI), calculated from the median fluorescence intensity (MFI) of samples incubated with prostaglandin E1 (PGE1) or PGE1 and ADP according to the formula PRI = ((MFIPGE1 − MFIPGE1 + ADP)/MFIPGE1) × 100. Patients were considered to have a low platelet response to clopidogrel (low-responder) if their PRI was \>50%, and a normal response to clopidogrel (responder) if their PRI was ≤50% as previously described \[[@B9-jcm-08-00506]\]. Analysis of CT-ADP with the primary haemostasis point-of-care assay PFA-100 (Siemens Healthcare) was performed according to the manufacturer's recommendations. In the setting of TAVR, this point-of-care assay is mainly used as a surrogate marker of high molecular weight von Willebrand defect.

2.4. CT Acquisition Protocol {#sec2dot4-jcm-08-00506}
----------------------------

Pre- and post-TAVI ECG-gated MDCT examinations were performed using a second- or third- generation 320-row CT scanner (Aquilion ONE Vision Edition, Aquilion One Genesis, Canon Medical Systems, Japan). The aortic root CT angiography was acquired in volume mode using a retrospective ECG-gated acquisition and the following CT parameters: 16 cm width, 100 kV for pre-TAVI and 135 kV for post-TAVI, gantry rotation time of 0.275 s, auto-mA maxed at 300, acquisition over 1 heartbeat. Acquisition was obtained after a bolus injection of 50 to 70 mL of iomeprol 400 mg/mL (Iomeron®, Bracco, Italy), using an automatic power injector at a rate of 3.5 mL/s, followed by 30 mL of saline chaser at a rate of 3 mL/s. The acquisition was triggered using a bolus-tracking technique with a Region of Interest (ROI) positioned in the descending thoracic aorta and a 180 Hounsfield Units (HU) threshold. Aortic valve calcium score and aortic valve annulus sizing were determined on the pre-TAVR CT by one radiologist using Vitrea software in version 6.6 (Vital Imaging, Minnetonka, MN, USA).

CT imaging definition of SLT was defined according to previous definitions \[[@B6-jcm-08-00506]\]. We first began to evaluate leaflet thickening (i.e., HALT) in diastole in two reconstructed planes. In the event of HALT, maximal leaflet thickening and the number of leaflets implicated were recorded. RELM was determined using cine reconstructions. Post-TAVR CT analysis was done in a consensus reading session with 1 experienced cardiac radiologist (MO, with 12 years of experience in CT) and 1 cardiologist (CJ, with 1 year of experience in CT) using a dedicated workstation (Vitrea version 6.6).

2.5. Echocardiography Assessment {#sec2dot5-jcm-08-00506}
--------------------------------

Transthoracic echocardiography (TTE) was performed at baseline, discharge, 1 and 12 months follow-up at the local echocardiography laboratory (Nouvel Hôpital Civil, Université de Strasbourg, France). Prosthetic assessment was done following current recommendations and guidelines of the American Society of Echocardiography \[[@B10-jcm-08-00506]\]. Left ventricle ejection fraction (LVEF), left ventricle dimensions, left atrial volume, mean aortic transvalvular gradient, permeability index, cardiac output, acceleration aortic time, and effective surface area were recorded.

2.6. Blood Collection and Laboratory Assays {#sec2dot6-jcm-08-00506}
-------------------------------------------

Whole blood samples were collected by venipuncture the day before and 24 and 72 h after TAVR and at discharge.

2.7. Collection of Data {#sec2dot7-jcm-08-00506}
-----------------------

All data, at baseline and during follow-up, were collected retrospectively according to the Valve Academic Research Consortium-2 criteria \[[@B11-jcm-08-00506]\]. The primary endpoint of the study was to determine the prevalence of SLT (HAM ± postprocedural elevation in transvalvular gradient) according to anticoagulant and antiplatelet therapy. The secondary endpoint was to determine predictive factors of HAM. In addition, we investigated the prevalence of HALT. In the event of HAM, antithrombotic treatment (VKA or NOACs) was initiated and a new CT scan was performed few months later to assess consistent regression of HAM images and restored leaflet motion.

2.8. Statistical Analysis {#sec2dot8-jcm-08-00506}
-------------------------

Categorical variables are expressed as numbers (%), and continuous variables are expressed as mean ± SD or median and interquartile values. Differences between the groups, consisting of HAM+ vs. HAM− and HALT+ vs. HALT− were assessed with χ^2^ tests for categorical variables. Unpaired Student's *t*-test was used to analyse continuous variables that showed normal distributions, and the Mann--Whitney test was used to analyse continuous variables with skewed distributions. Univariate and multivariate analysis was performed to identify independent predictors of HAM+. Variables with a univariate *p* \< 0.05 were considered for subsequent multivariate models. A *p*-value \< 0.05 was considered significant. Statistical analysis was performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).

3. Results {#sec3-jcm-08-00506}
==========

3.1. Study Cohort {#sec3dot1-jcm-08-00506}
-----------------

Out of 187 patients who underwent TAVR, post-TAVR MDCT was obtained in 90 patients after a median interval of 114 (65--205) days. MDCT met the quality criteria to identify HAM in 85 patients and in 86 patients for HALT. The flow chart of the study is given in [Figure 1](#jcm-08-00506-f001){ref-type="fig"}. CT reconstruction showing a normal appearance of the aortic valve; HALT without RELM and HAM images are illustrated in [Figure 2](#jcm-08-00506-f002){ref-type="fig"}.

3.2. Hypoattenuation Affecting Motion {#sec3dot2-jcm-08-00506}
-------------------------------------

HAM was evidenced in 13 patients (15.3%). Among them, only four patients (30.7%) had altered transvalvular gradients (mean gradient ≥20 mmHg and/or a change in gradient ≥10 mmHg compared to baseline values).

Baseline clinical, echocardiographic, MDCT, procedural, and biological characteristics according to HAM stratification (HAM+ and HAM−) are displayed in [Table 1](#jcm-08-00506-t001){ref-type="table"} and [Table 2](#jcm-08-00506-t002){ref-type="table"}. Patients were mainly women (67.1%), 82.1 ± 6.04 years old with a mean STS score of 4.3 ± 3.4%. The mean LVEF was 56% and the mean aortic gradient 44.8 ± 12.1 mmHg. CT aortic annulus area was similar in the two groups (495 ± 104 vs. 514 ± 154 mm^2^, *p* = 0.635), and the mean aortic valve calcium score was 2292 ± 1373 HU. TAVR was performed through transfemoral access in 79 (92.9%) patients and through transcarotid approach in six (7.1%) patients. There was no difference in heparin doses and activated clotting time (ACT) values during the procedures. Sapiens valves (71.8%) were mainly used in this study with similar rates of implantation among groups. Postprocedural evaluations of platelet inhibition by PRI-VASP (specific to P2Y~12~ inhibition) and occlusion time by CT-ADP point-of-care assay (sensitive not only to P2Y~12~ inhibition but also to several confounding factors, such as von Willebrand factor, platelet count, and haematocrit) were similar between groups. The proportion of HAM was 15.9% in Low Responder patients to clopidogrel (PRI-VASP \> 50%) and 13.6% in Responder patients (*p* = 0.530). At hospital discharge, haemoglobin (Hb) and creatine levels were higher in HAM+ patients.

Antithrombotic therapies at hospital discharge are summarized in [Table 3](#jcm-08-00506-t003){ref-type="table"}. The prevalence of HAM was lower among patients under OAC (only 1 patient was on VKA (7.7%), *p* = 0.012) compared to those with DAPT (12 (92.3%) of 13, *p* = 0.005). By multivariable analysis, lack of OAC and higher Hb levels were the sole independent predictors of HAM occurrence. By contrast, no impact of PRI-VASP nor CT-ADP on HAM occurrence could be demonstrated ([Table 4](#jcm-08-00506-t004){ref-type="table"}). The distribution of occlusion time, measured by the CT-ADP, and platelet inhibition by PRI-VASP, according to HAM, are represented [Figure 3](#jcm-08-00506-f003){ref-type="fig"} and [Figure 4](#jcm-08-00506-f004){ref-type="fig"}.

In case of SLT, DAPT was switched to conventional anticoagulant therapy (VKA or NOACs). Among the 13 patients with SLT, follow-up MDCT could only be obtained in four patients, three to nine months later. In all four cases, CT showed a complete regression of HAM after completing anticoagulation therapy.

Thirty-day post-TAVR echocardiograms and one-year follow-up are represented in [Table 5](#jcm-08-00506-t005){ref-type="table"}. At one-month follow-up, the two subsets of patients showed similar mean aortic transvalvular gradients (10.9 ± 5.6 vs. 12.6 ± 6.1 mmHg; *p* = 0.327), indexed aortic valve areas (1.06 ± 0.3 vs. 1.1 ± 0.3 cm^2^/m^2^; *p* = 0.654), and aortic acceleration times (79 ± 20 vs. 80 ± 21 m/s; *p* = 0.80).

Clinical follow-up was obtained in 70 patients. One-year mortality, major adverse cardiac events (MACE), and bleeding events were comparable between the two groups. Likewise, no sur-risk of stroke could be evidenced in the HAM+ group. Altogether, in this cohort of limited size, nonsignificant impact of HAM on adverse outcome could be established ([Table 5](#jcm-08-00506-t005){ref-type="table"}).

3.3. Hypoattenuation Leaflet Thickening {#sec3dot3-jcm-08-00506}
---------------------------------------

MDCT quality enabled HALT assessment in 86 patients. HALT without RELM were evidenced in 30 patients (35%). The clinical, echocardiographic, MDCT, biological, and procedural characteristics for the two groups (HALT+ and HALT−) are shown in [Table 6](#jcm-08-00506-t006){ref-type="table"}. There was no significant difference between the two groups, especially in terms of OAC and antiplatelet therapy at discharge.

Platelet inhibition assessed by PRI-VASP and closure time by CT-ADP did not differ significantly between patients with and without HALT ([Figure 5](#jcm-08-00506-f005){ref-type="fig"} and [Figure 6](#jcm-08-00506-f006){ref-type="fig"}).

The one-year follow-up stratified by HALT is summarized [Table 7](#jcm-08-00506-t007){ref-type="table"}. No significant differences among patient's subset could be evidenced at one-year follow-up.

4. Discussion {#sec4-jcm-08-00506}
=============

4.1. Main Results {#sec4dot1-jcm-08-00506}
-----------------

The current report, drawn from a cohort of 90 patients, is among the first study to specifically evaluate the impact of platelet inhibition extent on the occurrence of subclinical leaflet thrombosis detected by MDCT. The salient results of the present study are (1) subclinical leaflet thrombosis is observed in a sizeable proportion of TAVR patients (15%) after a median follow-up of 114 (65--205) days; (2) lack of oral anticoagulant together with elevated Hb levels were evidenced as independent predictors of subclinical leaflet thrombosis; (3) occurrence of subclinical leaflet thrombosis was independent of the extent of platelet inhibition, as measured by the PRI-VASP or the CT-ADP assay; (4) no impact of subclinical leaflet thrombosis on clinical events could be established. Altogether, our findings suggest the main importance of OAC therapy in the prevention of subclinical leaflet thrombosis independently of platelet inhibition extent. The prevalence of HAM reported in the present study (15%), is consistent with recent data from SAVORY and RESOLVE large observational registries in which TAVR reduced leaflet motion could be evidenced in 11.9% of the cohort \[[@B12-jcm-08-00506]\]. In TAVR, important variations in the occurrence of SLT have been recently underlined, depending, in part, on the criteria used and the quality of MDCT acquisition. In the report by Sondergaard \[[@B13-jcm-08-00506]\], HALT was evidenced in 38.1% and complete HAM in 20.2% after 140 days. By contrast, other investigators have reported lower HALT rates ranging from 4% (Leetmaa T, Circ Cardiovasc Interv. 2015 \[[@B14-jcm-08-00506]\]), 7% (Hansson NC, JACC 2016 \[[@B15-jcm-08-00506]\]), to 10.3% (Pache G, Eur Heart J. 2016 \[[@B16-jcm-08-00506]\]). Of particular interest, recent data have underlined that leaflet thrombosis occurred more frequently in transcatheter bioprosthetic valves than surgical ones \[[@B12-jcm-08-00506]\].

The study of mechanisms involved in thrombus formation during TAVR is far beyond the scope of the present study. Among various hypotheses, it is likely that the thrombus formation is the result of a complex interplay involving calcifications, native anatomy, hemodynamic, flow stasis, haemostatic factors, procedural factors, and valve type. Interaction between the prosthetic valve consisting in a metallic stent frame and three biologics leaflets, into a native or bioprosthetic (valve in valve) aortic valve, would create a new anatomic geometry characterized by modifications of shear stress regimen and turbulence. It is likely that the formation of a neosinus (region between the native and transcatheter aortic valve leaflet) favouring blood stasis would provide an ideal reservoir for thrombus formation. Moreover, exposure of procoagulant factors by the native valve (including tissue factor or procoagulant microparticles) may contribute to trigger thrombotic process. As pointed at by Midha et al. \[[@B17-jcm-08-00506]\] supra-annular position of the neosinus may reduce thrombotic potential owing to the reduction of blood stasis. Another important factor relies on the under expansion of the prosthesis as underlined in Sapiens 3 valves or in autopsy studies \[[@B18-jcm-08-00506]\]. Moreover, the possible contribution of valve injury mediated by balloon valvuloplasty or inflammatory response in thrombosis onset remains to be determined \[[@B19-jcm-08-00506]\]. Others authors have suggested that the structure composition of the valves may play a differential role in thrombus formation. Whilst CoreValve porcine pericardium valve contains a nickel and titanium alloy, the Edward Sapien bovine pericardium valve has a polyethylene terephthalate skirt and cobalt chromium stent that could trigger allergic reaction, IgE antibody formation, and the coagulation cascade \[[@B20-jcm-08-00506]\]. Finally, the contribution of paravalvular leak as a main determinant of platelet activation has recently be underlined \[[@B21-jcm-08-00506]\].

As extensively demonstrated in PCI, we sought to investigate whether impaired platelet inhibition evaluated either by PRI-VASP or by CT-ADP could contribute to subclinical leaflet thrombosis. In TAVR, we have previously demonstrated that prolonged CT-ADP (\>180 s) is not only a marker or paravalvular leakage (through enhanced proteolysis of high molecular weight von Willebrand factors) but also constitutes an integrate marker of enhanced periprocedural and late bleeding risk \[[@B22-jcm-08-00506],[@B23-jcm-08-00506]\]. In our hand no impact of impaired platelet inhibition of HAM and HALT phenomenon could be established. This result is consistent with the recent study from Nührenberg et al. \[[@B24-jcm-08-00506]\], which did not find significant association between the occurrence of HALT and impaired platelet inhibition assessed by ADP test. In the present study, the mean CT-ADP at discharge was 149 s which is comparable with data from Nührenberg and coworkers, but also with those from patients with coronary artery disease \[[@B7-jcm-08-00506]\]. Altogether, our finding suggests that the development of bioprosthetic valve thrombosis is mainly platelet independent, consistent with a primary role of contact phase activation and more likely to be targeted by OAC.

Among various factors possibly involved in the development of SLT, converging evidences have highlighted a key role of anticoagulant therapy in the prevention or treatment of silent valve thrombosis. In the RESOLVE and SAVORY registries, subclinical leaflet thrombosis was less frequent among patients treated by OAC (4%) than patients receiving DAPT (15%). In this report, SLT resolved in all patients receiving anticoagulant either by VKA or NOACS, whereas it persisted in 91% of patients under antiplatelet therapy alone. Similarly, in our experience, HAM could only be evidenced in 7.7% patients under OAC. Multivariable analysis confirmed the independent association between lack of OAC at hospital discharge and HAM phenomenon. Accordingly, in a larger registry by Hansson \[[@B15-jcm-08-00506]\] and coworkers, lack of warfarin treatment was also pointed out as an independent predictor of valve thrombosis. To date, important controversies remain on the impact of valve thrombosis on aortic valve pressure gradients, valve deterioration and adverse clinical outcomes. In the present report, mean aortic gradient at 30-day and one-year follow-up were not significantly different among groups. However, significant elevation of the mean aortic transvalvular gradient could be evidenced in 4 HAM patients (30.7%). Accordingly, in the report by Chakravarty \[[@B12-jcm-08-00506]\], an increase in aortic valve gradient could be evidenced in 14% of patients with subclinical leaflet thrombosis. Other authors have emphasized the view that the treatment with OAC leads not only to regression of valve thickening but also on changes in transvalvular pressure gradients \[[@B25-jcm-08-00506]\]. In the setting of TAVR, the question of valve durability remains of paramount importance. From a pathophysiological point of view, it is likely that endothelial damage and subsequent thrombosis may contribute to the infiltration of inflammatory cells within the valvular tissue leading to adverse remodeling and deterioration. Consistent with this paradigm, recent pathological analysis of 23 explanted transcatheter heart valves has underlined the existence of a time-dependent degeneration of heart valve consisting of thrombus formation, endothelial hyperplasia, fibrosis, tissue remodeling, proteinase expression, and calcification \[[@B26-jcm-08-00506]\]. In line with this view, registry data from a cohort of 1521 TAVI patients has elegantly depicted that the rate of valve deterioration, as assessed by elevation in mean transvalvular gradient was 2.8% at one year following TAVR. Of paramount importance, the absence of anticoagulation therapy at discharge was evidenced as a key factor of valve deterioration, together with valve in valve procedure and the use of small 23-mm valve \[[@B27-jcm-08-00506]\]. Although the contribution of confounding factors is difficult to delineate precisely in a prospective registry (OAC is mainly given in AF patients, AF could lead to gradient underestimation, and subsequently could underestimate valve deterioration in OAC receiving patients), those findings suggest that OAC are of paramount importance in the development of valve deterioration overt time.

Another crucial issue relies on the clinical impact of valve thrombosis on thromboembolic events. The pioneering work by Chakravarty \[[@B12-jcm-08-00506]\] has suggested that SLT was associated with increased rates of transient ischemic attack (TIA). Conversely, in a large registry comprising 754 patients (among them 120 patients with valve thrombosis), no differences in overall mortality and stroke/TIA rates could be demonstrated after a 406-day follow-up. However, it should be emphasized that rates of stroke/TIA were surprisingly extremely low (\<2%) for a TAVR population \[[@B28-jcm-08-00506]\], which probably reflects the German policy characterized by a more liberal use of TAVR implantation that includes lower risk patients. By contrast, insights from the US FDA MAUDE database has highlighted that leaflet thrombosis is associated with adverse outcomes including stroke, cardiogenic shock and death \[[@B29-jcm-08-00506]\].

The definition of optimal antithrombotic therapies following TAVR remains a matter of important controversies. Whereas the frequency of subclinical leaflet thrombosis and the possible link between SLT and valve deterioration advocate for a liberal use of OAC, safety concerns and the assessment of bleeding events remain key elements when prescribing OAC. Several groups including ours have recently underlined the paramount importance of bleeding events that significantly outweighed ischemic concerns \[[@B23-jcm-08-00506],[@B24-jcm-08-00506],[@B25-jcm-08-00506],[@B26-jcm-08-00506],[@B27-jcm-08-00506],[@B28-jcm-08-00506],[@B29-jcm-08-00506],[@B30-jcm-08-00506]\]. Of major importance, late bleeding is considered as a main determinant of adverse outcome in the frail TAVR population. Ongoing trials (ATLANTIS trial NCT02943785, POPular-TAVI trial NCT02247128, ENVISAGE-TAVI trial NCT02943785, AUREA trial NCT01642134, and AVATAR trial NCT02735902) will provide important insights on the efficacy but also safety profile of OAC including NOACS. However, alerting signal was very recently provided by the GALILEO trial which was prematurely halted. In this study, RIVAROXABAN, a Xa inhibitor was associated with greater risk of all-cause mortality, thromboembolic events, and bleeding in TAVR patients.

4.2. Study Limitations {#sec4dot2-jcm-08-00506}
----------------------

Several limitations should be taken into account in the interpretation of the data: (i) HAM and HALT are considered as surrogate markers of SLT and pathological evidences for SLT could not be established; (ii) antithrombotic therapy was not randomized; (iii) CKD patients with eGFR \< 30 mL/min/1.73 m^2^ were excluded from the analysis; (iv) timing between the two MDCT was not standardized; (v) follow-up was only obtained in 70 (82% patients); and (vi) given the limited size of the cohort, analysis should be interpreted with caution and the findings viewed as exploratory and hypothesis generating.

5. Conclusions {#sec5-jcm-08-00506}
==============

SLT is evidenced in a sizeable proportion of patients treated by TAVR and is mainly determined the lack of anticoagulant therapy. Conversely, no impact of platelet inhibition extent on SLT could be evidenced. Ongoing randomized prospective studies will provide important insights on the optimal antithrombotic strategy after TAVR.
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![Flowchart of the study. Abbrevations: eGFR: estimated glomerular filtration rate; HAM: hypoattenution affecting motion; HALT: hypoattuated leaflet thickening; MDCT: multidetector computed tomography; TAVR: Transcatheter aortic valve replacement.](jcm-08-00506-g001){#jcm-08-00506-f001}

![(**a**) MDCT images of normal (without HALT) Edward Sapien prosthesis in diastolic (short axis, A, and long axis, B) and in systolic (long axis, C, and short axis, D) phases. (**b**) MDCT images of HALT + (red arrow) RELM- in diastolic (short axis A, and long B axis) and in systolic (short axis, C, and long axis, D) phases. (**c**) MDCT images of HAM+ prosthesis: HALT+ (red arrow) and RELM + in diastolic (short axis, A, and long axis, B) and systolic (short axis, C, and long axis, D) phases.](jcm-08-00506-g002){#jcm-08-00506-f002}

![Occlusion time by CT-ADP according to the occurrence of HAM.](jcm-08-00506-g003){#jcm-08-00506-f003}

![Platelet inhibition by PRI-VASP according to the occurrence of HAM.](jcm-08-00506-g004){#jcm-08-00506-f004}

![Occlusion time by CT-ADP according to the occurrence of HALT.](jcm-08-00506-g005){#jcm-08-00506-f005}

![Occlusion time by VASP according to the occurrence of HALT.](jcm-08-00506-g006){#jcm-08-00506-f006}

jcm-08-00506-t001_Table 1

###### 

Baseline clinical, echocardiographic, and procedural characteristics according to HAM occurrence.

  Characteristics                            Total (*n* = 85)   HAM− (*n* = 72)   HAM+ (*n* = 13)   *p*-Value
  ------------------------------------------ ------------------ ----------------- ----------------- -----------
  Age-y                                      82.1 ± 6.04        82.1 ± 6.2        81.8 ± 5.6        0.919
  Male sex-no (%)                            28 (32.9)          23 (31.9)         5 (38.5)          0.645
  BMI kg/m^2^                                26.8 ± 6.1         27.2 ± 6.1        24.6 ± 5.8        0.15
  EuroSCORE II, %                            5.2 ± 4.3          5.5 ± 4.5         3.7 ± 2.5         0.168
  STS score (%)                              4.3 ± 3.4          4.3 ± 3.4         4.3 ± 3.4         0.829
  AF-no (%)                                  19 (22.6)          18 (25)           1 (8.3)           0.201
  CAD-no (%)                                 44 (53)            37 (52.9)         7 (53.8)          0.948
  CKD-no (%)                                 45 (52)            39 (54.2)         6 (46.2)          0.594
  Hypertension-no (%)                        69 (81.2)          59 (81.9)         10 (76.9)         0.670
  Current or former smoking history-no (%)   13 (15.3)          12 (16.7)         1 (7.7)           0.408
  Dyslipidaemia-no (%)                       53 (62.4)          45 (62.5)         8 (61.5)          0.947
  Diabetes mellitus-no (%)                   21 (24.7)          20 (27.8)         1 (7.7)           0.122
  TTE preprocedural measurements                                                                    
  LVEF, %                                    56.0 ± 13.2        55.9 ± 13.1       56.3 ± 14.7       0.934
  LVEDD, mm                                  50.1 ± 8.3         50.1 ± 8.3        50.2 ± 8.9        0.965
  AVAi, cm^2^/m^2^                           0.44 ± 0.14        0.44 ± 0.1        0.44 ± 0.1        0.924
  PI                                         0.2 ± 0.05         0.2 ± 0.1         0.2 ± 0.1         0.931
  MA transvalvular gradient, mmHg            44.8 ± 12.1        44.8 ± 12.4       45 ± 10.2         0.698
  LA volume, mL/m^2^                         18.3 ± 17.3        48.4 ± 17.4       48 ± 17.6         0.956
  SEVi, mL/m^2^                              42.8 ± 13.3        42.6 ± 13.6       43.9 ± 12.8       0.736
  CI mL/min/m^2^                             3.2 ± 1.3          3.2 ± 1.4         2.9 ± 0.6         0.508
  CT preprocedural measurements                                                                     
  Aortic annulus area, mm^2^                 499 ± 113          495 ± 104         514 ± 154         0.635
  Aortic valve calcium score, HU             2292 ± 1373        3034 ± 1448       2797 ± 989        0.626
  Procedural characteristics                                                                        
  Approach                                                                                          
  Transfemoral-no (%)                        79 (92.9)          67 (93.1)         12 (92.3)         0.923
  Transcarotid-no (%)                        6 (7.1)            5 (6.9)           1 (7.7)           0.923
  Predilatation-no (%)                       36 (42.4)          33 (45.8)         3 (23.1)          0.126
  Valve in valve-no (%)                      1 (1.2)            1 (1.4)           0 (0)             0.669
  Valve                                                                                             
  Sapien-no (%)                              61 (71.8)          50 (69.4)         11 (84.6)         0.263
  CoreValve-no (%)                           24 (28.2)          22 (30.6)         2 (15.4)          0.263
  Size valve                                                                                        
  Sapien N 23 mm (%)                         28 (32.9)          25 (34.7)         3 (23.1)          0.411
  Sapien N 26 mm (%)                         17 (20)            13 (18.1)         4 (30.8)          0.292
  Sapien N 29 mm (%)                         15 (17.6)          12 (16.7)         3 (23.1)          0.577
  CoreValve N 23 mm (%)                      2 (2.4)            2 (2.8)           0 (0)             0.543
  CoreValve N 26 mm (%)                      8 (9.4)            7 (9.7)           1 (7.7)           0.818
  CoreValve N 29 mm (%)                      10 (11.8)          9 (12.5)          1 (7.)            0.62
  CoreValve N 31 mm (%)                      1 (1.2)            1 (1.4)           0 (0)             0.669
  CoreValve N 34 mm (%)                      3 (3.5)            2 (2.8)           1 (7.7)           0.377
  Total Procedure time, min                  77.5 ± 26.2        78.2 ± 27.5       73.6 ± 17.1       0.593
  Heparin, mg                                232 ± 101          254 ± 110         111 ± 37          0.656
  ACT, sec                                   277 ± 90           283 ± 94          240 ± 57          0.148

Abbreviations: AAT: aortic acceleration time; AF: atrial fibrillation; AVAi: indexed aortic valve area; BMI: body mass index: CAD: coronary artery disease; CKD: chronic kidney disease (creatinine \> 150 µmol/L); CI: cardiac index; CT: computed tomography; HAM: hypoattenuation affecting motion; HU: Hounsfield units; LA: left atrial; LVEDD: left ventricle end diastole diameter; LVEF: left ventricle ejection function; MA: mean aortic; PI: permeability index; SEVi: stroke ejection volume index; TTE: transthoracic echocardiography.
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###### 

Biological characteristics.

  Characteristics      Total (*n* = 85)   HAM− (*n* = 72)   HAM+ (*n* = 13)   *p*-Value
  -------------------- ------------------ ----------------- ----------------- -----------
  Hb, g/dL                                                                    
  Baseline             12.4 ± 2.2         12.2 ± 2.0        13.0 ± 1.6        0.245
  Post-TAVR            10.14 ± 1.6        9.9 ± 1.5         11.1 ± 1.3        0.015
  Creatinine, µmol/L                                                          
  Baseline             113.9 ± 131.5      112.7 ± 133.9     121.2 ± 121.5     0.831
  At discharge         104.7 ± 109.3      94.5 ± 74.3       160 ± 216.5       0.043
  CT-ADP, s                                                                   
  Baseline             221.2 ± 77.7       218.6 ± 76.9      235.8 ± 86.4      0.499
  Post-TAVR            149.1 ± 73         147.2 ± 72.0      158.5 ± 79.8      0.769
  VASP, %                                                                     
  Post-TAVR            66.9 ± 18.4        68.0 ± 16.9       61.8 ± 24.6       0.274
  PRI-VASP \> 50%      63 (82.9)          53 (84.1)         10 (76.9)         0.530

Abbreviations: CT-ADP: closure time adenosine diphosphate; HAM: hypoattenuation affecting motion; Hb: Haemoglobin; PRI-VASP: platelet reactivity index vasodilator stimulated protein; TAVR: transcatheter valve replacement.
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###### 

HAM according to antithrombotic regimens.

  Antithrombotic Regimens                 Total (*n* = 85)   HAM− (*n* = 72)   HAM+ (*n* = 13)   *p*-Value
  --------------------------------------- ------------------ ----------------- ----------------- -----------
  Antithrombotic treatment before TAVR                                                           
  Antiplatelet therapy-no (%)             42 (49.4)          33 (45.8)         9 (69.2)          0.12
  OAC-no (%)                              29 (34.1)          28 (38.9)         1 (7.7)           0.029
  Antithrombotic treatment at discharge                                                          
  DAPT-no (%)                             48 (56.5)          36 (50)           12 (92.3)         0.005
  OAC-no (%)                              33 (38.8)          32 (44.4)         1 (7.7)           0.012

Abbreviations: DAPT: dual antiplatelet therapy; HAM: hypoattenuation affecting motion; OAC: oral anticoagulant; TAVR: transcatheter aortic valve replacement.
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###### 

Predictors of HAM.

  Characteristics            Univariate Analysis                   Multivariate Analysis                             
  -------------------------- --------------------- --------------- ----------------------- -------- ---------------- -------
  Age                        0.995                 0.903--1.096    0.917                                             
  Male sex                   1.332                 0.392--4.520    1.332                                             
  EuroSCORE II               0.829                 0.646--1.063    0.829                                             
  Diabetes mellitus          0.217                 0.026--1.777    0.154                                             
  BMI                        0.906                 0.795--1.032    0.138                                             
  Sapien valve               2.420                 0.495--11.842   0.275                                             
  Total procedure time       0.992                 0.965--1.020    0.589                                             
  UFH                        0.993                 0.973--1.014    0.526                                             
  Predilatation              0.355                 0.090--1.397    0.138                                             
  Lack of OAC at discharge   10.154                1.253--82.528   0.030                   12.130   1.394--150.582   0.028
  Creatinine at discharge    1.004                 0.999--1.008    0.092                                             
  CT-ADP                     1.002                 0.994--1.010    0.611                                             
  PRI-VASP \> 50%            0.629                 0.147--2.699    2.699                                             
  Hb at discharge            1.730                 1.101--2.719    0.017                   1.887    1.148--3.104     0.012

Abbreviations: BMI: body mass index; CI: confidence interval; CT-APD: closure time adenosine diphosphate; HAM: hypoattenuation affecting motion; Hb: haemoglobin; HR: hazard ratio; OAC: oral anticoagulant; PRI-VASP: platelet reactivity index-vasodilator stimulated; UFH: unfractionated heparin.
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###### 

Thirty-day TTE evaluation and one-year follow-up endpoints according to HAM occurrence.

  Follow-Up                             Total (*n* = 70)   HAM− (*n* = 58)   HAM+ (*n* = 12)   *p*-Value
  ------------------------------------- ------------------ ----------------- ----------------- -----------
  One-year follow-up endpoints                                                                 
  Mortality-no (%)                      1 (1.4)            1 (1.7)           0 (0)             0.647
  MACE+ Bleeding complications-no (%)   6 (8.7)            4 (7.0)           2 (16.7)          0.281
  Stroke and TIA-no (%)                 4 (5.8)            3 (5.3)           1 (8.3)           0.679
  Bleeding-no (%)                       3 (4.4)            2 (3.5)           1 (9.1)           0.409
  Rehospitalization-no (%)              32 (45.7)          25 (43.1)         7 (58.3)          0.335
  Heart failure-no (%)                  9 (12.9)           8 (13.8)          1 (8.3)           0.607
  AF-no (%)                             4 (5.8)            3 (5.3)           1 (8.3)           0.679
  30-Day post-TAVR TTE                                                                         
  LVEF, %                               58.1 ± 10.3        58.2 ± 10.6       57.7 ± 8.9        0.879
  MA transvalvular gradient, mmHg       11.2 ± 5.7         10.9 ± 5.6        12.6 ± 6.1        0.327
  PI                                    0.54 ± 0.2         0.54 ± 0.1        0.49 ± 0.2        0.262
  AVAi, cm^2^/m^2^                      1.06 ± 0.3         1.06 ± 0.3        1.1 ± 0.4         0.654
  AAT, m/s                              79 ± 20            79 ± 20           80 ± 21           0.800
  SEVi, mL/m^2^                         46.4 ± 13          45.6 ± 13         51.2 ± 10         0.145
  CI mL/min/m^2^                        3.6 ± 1.5          3.7 ± 1.6         3.4 ± 0.9         0.603
  1-Yeat post-TAVR TTE                                                                         
  LVEF, %                               58.6 ± 8.6         58.1 ± 9.0        60.7 ± 6.6        0.432
  MA transvalvular gradient, mmHg       10.9 ± 5.5         10.8 ± 5.7        11.5 ± 5.0        0.75
  PI                                    0.53 ± 0.2         0.53 ± 0.1        0.55 ± 0.2        0.643
  AVAi, cm^2^/m^2^                      0.99 ± 0.3         0.98 ± 0.3        1.06 ± 0.5        0.79
  AAT, m/s                              77.9 ± 15.5        77.7 ± 15.7       79.6 ± 15.7       0.805
  SEVi, mL/m^2^                         43.9 ± 10.0        44.3 ± 10.0       42.5 ± 10.9       0.702
  CI mL/min/m^2^                        3.2 ± 1.1          2.9 ± 1.0         3.9 ± 1.1         0.045

Abbreviations: AAT: aortic acceleration time; AF: atrial fibrillation; AVAi: indexed aortic valve area; CI: cardiac index; HAM: hypoattenuation affecting motion; LVEF: left ventricle ejection function; MA: mean aortic; MACE: major adverse cardiac events; TAVR: transcatheter aortic valve replacement; TIA: transient ischemic attack; TTE: transthoracic echocardiography; PI: permeability index; SEVi: stroke ejection volume index.
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###### 

Clinical baseline, echocardiographic, biological, and procedural characteristics for HALT.

  Characteristics                            Total (*n* = 86)   HALT− (*n* = 56)   HALT+ (*n* = 30)   *p*-Value
  ------------------------------------------ ------------------ ------------------ ------------------ -----------
  Age- y                                     82.1 ± 6.02        81.9 ± 6.7         82.5 ± 4.5         0.651
  Male sex-no (%)                            28 (32.6)          16 (28.6)          12 (40)            0.281
  BMI kg/m^2^                                26.8 ± 6.1         27.6 ± 6.2         25.2 ± 5.6         0.083
  EuroSCORE II, %                            5.5 ± 4.7          5.7 ± 4.7          4.9 ± 4.8          0.47
  AF-no (%)                                  19 (22.4)          13 (23.2)          6 (20.7)           0.791
  CAD-no (%)                                 45 (53.6)          29 (52.7)          16 (55.2)          0.831
  CKD-no (%)                                 46 (53.5)          31 (55.4)          15 (50)            0.635
  Hypertension-no (%)                        70 (81.4)          46 (82.1)          24 (80)            0.808
  Current or former smoking history-no (%)   13 (15.1)          10 (17.9)          3 (10)             0.332
  Dyslipidaemia-no (%)                       54 (62.8)          35 (62.5)          19 (63.3)          0.939
  Diabetes mellitus-no (%)                   21 (24.4)          15 (26.8)          6 (20)             0.485
  TTE preprocedural measurements                                                                      
  LVEF, %                                    56.13              55.9 ± 12.7        56.5 ± 14.2        0.864
  LVEDD, mm                                  50.1 ± 8.3         49.6 ± 8.7         51.1 ± 7.4         0.452
  AVAi, cm^2^/m^2^                           0.44 ± 0.1         0.44 ± 0.2         0.44 ± 0.1         0.882
  PI                                         0.2 ± 0.05         0.2 ± 0.05         0.19 ± 0.04        0.434
  MA transvalvular gradient, mmHg            44.8 ± 12.0        44.6 ± 13.0        45.1 ± 10.1        0.861
  LA volume, mL/m^2^                         48.6 ± 17.3        47.1 ± 17.9        51.3 ± 16.4        0.321
  SEVi, mL/m^2^                              42.9 ± 13.3        43.4 ± 13.7        42.1 ± 12.8        0.687
  CI mL/min/m^2^                             3.2 ± 1.2          3.2 ± 1.1          3.2 ± 1.5          0.793
  CT preprocedural measurements                                                                       
  Aortic annulus area, mm^2^                 498.3 ± 112        494.6 ± 98         502.8 ± 123        0.790
  Aortic valve calcium score, HU             2991 ± 1376        3126 ± 1608        2513 ± 981         0.404
  Procedural characteristics                                                                          
  Approach                                                                                            
  Transfemoral-no (%)                        80 (93)            51 (91.1)          29 (96.7)          0.332
  Transcarotid- no (%)                       6 (7)              5 (8.9)            1 (3.3)            0.332
  Valve in valve procedure-no (%)            2 (2.3)            1 (1.8)            1 (3.3)            0.65
  Valve                                                                                               
  Sapien-no (%)                              61 (70.9)          38 (67.9)          23 (76.7)          0.391
  CoreValve-no (%)                           25 (29.1)          18 (32.1)          7 (23.3)           0.391
  Size valve                                                                                          
  Sapien N 23 mm (%)                         28 (32.6)          21 (37.5)          7 (23.3)           0.181
  Sapien N 26 mm (%)                         17 (19.8)          9 (16.1)           8 (26.7)           0.24
  Sapien N 29 mm (%)                         15 (17.4)          8 (14.3)           7 (23.3)           0.292
  CoreValve N 23 mm (%)                      3 (3.5)            2 (3.6)            1 (3.3)            0.954
  CoreValve N 26 mm (%)                      8 (9.3)            5 (8.9)            3 (10)             0.87
  CoreValve N 29 mm (%)                      10 (11.6)          7 (12.5)           3 (10)             0.73
  CoreValve N 31 mm (%)                      1 (1.2)            1 (1.8)            0 (0)              0.462
  CoreValve N 34 mm (%)                      3 (3.5)            2 (3.6)            1 (3.3)            0.954

Abbreviations: AAT: aortic acceleration time; AF: atrial fibrillation; AVAi: indexed aortic valve area; BMI: body mass index; CAD: coronary artery disease; CKD: chronic kidney disease (creatinine \>150 µmol/L); CI: cardiac index; CT: computed tomography; HALT: hypoattenuated leaflet thickening; HU: Hounsfield units; LA: left atrial; LVEDD: left ventricle end diastole diameter; LVEF: left ventricle ejection function; MA: mean aortic; PI: permeability index; SEVi: stroke ejection volume index; TTE: transthoracic echocardiography.
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###### 

HALT at 30-day and 1-year follow-up.

  Follow-Up                              Total (*n* = 70)   HALT− (*n* = 46)   HALT+ (*n* = 24)   *p*-Value
  -------------------------------------- ------------------ ------------------ ------------------ -----------
  1-Year follow-up endpoints                                                                      
  Mortality-no (%)                       1 (1.4)            1 (2.1)            0 (0)              0.471
  MACE + Bleeding complications-no (%)   7 (10)             4 (8.7)            3 (12.5)           0.568
  Stroke and TIA-no (%)                  4 (5.7)            3 (6.5)            1 (4.2)            0.697
  Bleeding-no (%)                        4 (5.8)            1 (2.2)            3 (13)             0.015
  Rehospitalization-no (%)               33 (46.5)          18 (39.1)          15 (60)            0.121
  Heart failure-no (%)                   10 (14.1)          6 (13)             4 (16)             0.777
  AF-no (%)                              5 (7.1)            2 (4.4)            3 (12)             0.089
  30-Day post-TAVR TTE                                                                            
  LVEF, %                                58.2 ± 10.3        58.6 ± 10.8        57.4 ± 9.5         0.598
  MA transvalvular gradient, mmHg        11.1 ± 5.5         10.9 ± 5.4         11.6 ± 5.7         0.57
  PI                                     0.54 ± 0.15        0.56 ± 0.15        0.50 ± 0.15        0.08
  AVAi, cm^2^/m^2^                       1.06 ± 0.3         1.06 ± 0.3         1.05 ± 0.4         0.878
  AAT, m/s                               79.1 ± 19.9        79.9 ± 20.7        77.4 ± 18.6        0.606
  SEVi, mL/m^2^                          46.2 ± 13.2        45.3 ± 13.2        48.01 ± 12.8       0.402
  CI mL/min/m^2^                         3.6 ± 1.5          3.7 ± 1.6          3.4 ± 1.3          0.553
  1-Year post-TAVR TTE                                                                            
  LVEF, %                                58.6 ± 8.6         57.7 ± 9.7         60.2 ± 5.9         0.367
  MA transvalvular gradient, mmHg        10.9 ± 5.5         11 ± 5.8           10.8 ± 5.1         0.911
  PI                                     0.53 ± 0.14        0.52 ± 0.14        0.55 ± 0.17        0.653
  AVAi, cm^2^/m^2^                       0.99 ± 0.34        0.98 ± 0.34        1.01 ± 0.35        0.832
  AAT, m/s                               77.9 ± 15.5        76.7 ± 15.5        80.8 ± 15.6        0.46
  SEVi, mL/m^2^                          43.9 ± 10          49 ± 9.5           41 ± 10.5          0.224
  CI mL/min/m^2^                         3.2 ± 1.1          3.1 ±1             3.2 ± 1.1          0.801

Abbreviations: AAT: aortic acceleration time; AF: atrial fibrillation; AVAi: indexed aortic valve area; CI: cardiac index; HALT: hypoattenuated leaflet thickening; LVEF: left ventricle ejection function; MA: mean aortic; MACE: major adverse cardiac events; TIA: transient ischemic attack; TTE: transthoracic echocardiography; PI: permeability index; SEVi: stroke ejection volume index.
